Literature DB >> 18843590

Selective estrogen receptor modulators and phytoestrogens.

Tawakalitu Oseni1, Roshani Patel, Jennifer Pyle, V Craig Jordan.   

Abstract

Scientific achievements in the last two decades have revolutionized the treatment and prevention of breast cancer. This is mainly because of targeted therapies and a better understanding of the relationship between estrogen, its receptor, and breast cancer. One of these discoveries is the use of synthetic selective estrogen modulators (SERMs) such as tamoxifen in the treatment strategy for estrogen receptor (ER)-positive breast cancer. Hundreds of thousands of lives have been saved because of this advance. Not only is tamoxifen used in the treatment strategy for patients who have breast cancer, but also for prevention in high-risk premenopausal women. Another synthetic SERM, raloxifene, which was initially used to prevent osteoporosis, is also as effective as tamoxifen for prevention in high-risk postmenopausal women. In certain regions of the world, particularly in Asia, a low incidence of breast cancer has been observed. These women have diets that are high in soy and low in fat, unlike the Western diet. Interest in the protective effects of soy derivatives has led to the research of phytoestrogens and metabolites of soy that are described by some as natural SERMs. As a result, many clinical questions have been raised as to whether phytoestrogens, which are also found in other natural foods, can protect against breast cancer. This article reviews the development and role of the more common SERMs, tamoxifen and raloxifene. In addition, this paper will also highlight the emerging studies on phytoestrogens and their similarity and dissimilarity to SERMs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18843590      PMCID: PMC2587438          DOI: 10.1055/s-0028-1088304

Source DB:  PubMed          Journal:  Planta Med        ISSN: 0032-0943            Impact factor:   3.352


  119 in total

1.  Soyfood intake during adolescence and subsequent risk of breast cancer among Chinese women.

Authors:  X O Shu; F Jin; Q Dai; W Wen; J D Potter; L H Kushi; Z Ruan; Y T Gao; W Zheng
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2001-05       Impact factor: 4.254

2.  Effects of the dietary phytoestrogen biochanin A on cell growth in the mammary carcinoma cell line MCF-7.

Authors:  J T Hsu; H C Hung; C J Chen; W L Hsu; C Ying
Journal:  J Nutr Biochem       Date:  1999-09       Impact factor: 6.048

Review 3.  Antiestrogens and selective estrogen receptor modulators as multifunctional medicines. 2. Clinical considerations and new agents.

Authors:  V Craig Jordan
Journal:  J Med Chem       Date:  2003-03-27       Impact factor: 7.446

4.  Effects of anti-estrogens on bone in castrated and intact female rats.

Authors:  V C Jordan; E Phelps; J U Lindgren
Journal:  Breast Cancer Res Treat       Date:  1987-10       Impact factor: 4.872

Review 5.  Should clinicians be concerned about the carcinogenic potential of tamoxifen?

Authors:  V C Jordan; M Morrow
Journal:  Eur J Cancer       Date:  1994       Impact factor: 9.162

6.  Endoxifen, a secondary metabolite of tamoxifen, and 4-OH-tamoxifen induce similar changes in global gene expression patterns in MCF-7 breast cancer cells.

Authors:  Young Chai Lim; Lang Li; Zeruesenay Desta; Qianqian Zhao; James M Rae; David A Flockhart; Todd C Skaar
Journal:  J Pharmacol Exp Ther       Date:  2006-05-11       Impact factor: 4.030

7.  Characterization of raloxifene glucuronidation in vitro: contribution of intestinal metabolism to presystemic clearance.

Authors:  Daniel C Kemp; Peter W Fan; Jeffrey C Stevens
Journal:  Drug Metab Dispos       Date:  2002-06       Impact factor: 3.922

8.  Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial.

Authors:  Trevor J Powles; Sue Ashley; Alwynne Tidy; Ian E Smith; Mitch Dowsett
Journal:  J Natl Cancer Inst       Date:  2007-02-21       Impact factor: 13.506

9.  Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene.

Authors:  Silvana Martino; Jane A Cauley; Elizabeth Barrett-Connor; Trevor J Powles; John Mershon; Damon Disch; Roberta J Secrest; Steven R Cummings
Journal:  J Natl Cancer Inst       Date:  2004-12-01       Impact factor: 13.506

10.  Tamoxifen and bone metabolism in postmenopausal low-risk breast cancer patients: a randomized study.

Authors:  B Kristensen; B Ejlertsen; P Dalgaard; L Larsen; S N Holmegaard; I Transbøl; H T Mouridsen
Journal:  J Clin Oncol       Date:  1994-05       Impact factor: 44.544

View more
  56 in total

1.  Soy isoflavone phase II metabolism differs between rodents and humans: implications for the effect on breast cancer risk.

Authors:  Kenneth D R Setchell; Nadine M Brown; Xueheng Zhao; Stephanie L Lindley; James E Heubi; Eileen C King; Mark J Messina
Journal:  Am J Clin Nutr       Date:  2011-09-28       Impact factor: 7.045

Review 2.  DNA microarray-based gene expression profiling of estrogenic chemicals.

Authors:  Ryoiti Kiyama; Yun Zhu
Journal:  Cell Mol Life Sci       Date:  2014-01-08       Impact factor: 9.261

Review 3.  The pros and cons of phytoestrogens.

Authors:  Heather B Patisaul; Wendy Jefferson
Journal:  Front Neuroendocrinol       Date:  2010-03-27       Impact factor: 8.606

4.  Role of cholesterol in the development and progression of breast cancer.

Authors:  Gemma Llaverias; Christiane Danilo; Isabelle Mercier; Kristin Daumer; Franco Capozza; Terence M Williams; Federica Sotgia; Michael P Lisanti; Philippe G Frank
Journal:  Am J Pathol       Date:  2010-12-23       Impact factor: 4.307

5.  Serum free estradiol and estrogen receptor-α mediated activity are related to decreased incident hip fractures in older women.

Authors:  Vanessa W Lim; Jun Li; Yinhan Gong; Jian-Min Yuan; Tsung Sheng Wu; Geoffrey L Hammond; Aizhen Jin; Woon-Puay Koh; E L Yong
Journal:  Bone       Date:  2012-03-16       Impact factor: 4.398

Review 6.  Role of phytoestrogens in cancer therapy.

Authors:  Mandeep K Virk-Baker; Tim R Nagy; Stephen Barnes
Journal:  Planta Med       Date:  2010-07-01       Impact factor: 3.352

Review 7.  Nuclear receptors and epigenetic regulation: opportunities for nutritional targeting and disease prevention.

Authors:  Donato F Romagnolo; Janos Zempleni; Ornella I Selmin
Journal:  Adv Nutr       Date:  2014-07-14       Impact factor: 8.701

8.  Treatment with qibaomeiran, a kidney-invigorating Chinese herbal formula, antagonizes estrogen decline in ovariectomized rats.

Authors:  Ying Xu; Xiao-ping Ma; Jie Ding; Zhen-li Liu; Zhi-qian Song; Hong-ning Liu; Na Lin
Journal:  Rejuvenation Res       Date:  2014-08       Impact factor: 4.663

Review 9.  Does soy protein affect circulating levels of unbound IGF-1?

Authors:  Mark Messina; Pamela Magee
Journal:  Eur J Nutr       Date:  2017-04-22       Impact factor: 5.614

10.  Comparative Developmental Toxicity of Flavonoids Using an Integrative Zebrafish System.

Authors:  Sean M Bugel; Josephine A Bonventre; Robert L Tanguay
Journal:  Toxicol Sci       Date:  2016-08-04       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.